TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE HEPARIN MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 EUROPE HEPARIN MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 MARKET APPLICATION COVERAGE GRID
2.9 DBMR VENDOR SHARE ANALYSIS
2.10 MULTIVARIATE MODELING
2.11 PRODUCTS LIFELINE CURVE
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 MARKET OVERVIEW
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 REGULATORY PROCEDURE
7 EUROPE HEPARIN MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 UNFRACTIONATED HEPARIN
7.3 LOW MOLECULAR WEIGHT HEPARIN
7.3.1 ENOXAPARIN
7.3.2 DALTEPARIN
7.3.3 TINZAPARIN
7.3.4 FRAXIPARINE
7.3.5 OTHERS
7.4 ULTRA-LOW MOLECULAR WEIGHT HEPARIN
7.4.1 SEMULOPARIN
7.4.2 BEMIPARIN
7.4.3 OTHERS
8 EUROPE HEPARIN MARKET, BY MODE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.3 PARENTERAL ADMINISTRATION
8.3.1 SUBCUTANEOUS
8.3.2 INTRAVENOUS
8.3.3 INTRAPERITONEAL
8.3.4 OTHERS
9 EUROPE HEPARIN MARKET, BY SOURCE
9.1 OVERVIEW
9.2 BOVINE
9.3 PORCINE
10 EUROPE HEPARIN MARKET, BY INGREDIENTS
10.1 OVERVIEW
10.2 SODIUM
10.3 CALCIUM
10.4 OTHERS
11 EUROPE HEPARIN MARKET, BY AVAILABILITY
11.1 OVERVIEW
11.2 RAW
11.3 PROCESSED
12 EUROPE HEPARIN MARKET, BY TREATMENT
12.1 OVERVIEW
12.2 DEEP VEIN THROMBOSIS (DVT)
12.3 PULMONARY EMBOLISM (PE)
12.4 ARTERIAL THROMBOEMBOLISM (AT)
12.5 OTHERS
?
13 EUROPE HEPARIN MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 PRE-SURGICAL PROCEDURES
13.3 POST-SURGICAL PROCEDURES
13.4 KIDNEY DIALYSIS
13.5 DIAGNOSTIC TESTS
13.6 OTHERS
14 EUROPE HEPARIN MARKET, BY THERAPEUTICS
14.1 OVERVIEW
14.2 CARDIOVASCULAR
14.3 RESPIRATORY
14.4 ONCOLOGY
14.5 NEPHROLOGY
14.6 CNS
14.7 OTHERS
15 EUROPE HEPARIN MARKET, BY STRENGTH
15.1 OVERVIEW
15.2 UNITS
15.3 UNITS
15.40 UNITS
15.50 UNITS
15.6,000 UNITS
15.7,000 UNITS
15.8 OTHERS
16 EUROPE HEPARIN MARKET, BY TYPE
16.1 OVERVIEW
16.2 GENERICS
16.3 BRANDED
16.3.1 LIPO-HEPIN
16.3.2 LIQUAEMIN
16.3.3 PANHEPARIN
16.3.4 HEP-LOCK
16.3.5 HEPALEAN (CALCIPARINE)
16.3.6 OTHERS
?
17 EUROPE HEPARIN MARKET, BY CONTAINER
17.1 OVERVIEW
17.2 BOTTLES
17.3 BAGS
17.4 VIALS
17.5 OTHERS
18 EUROPE HEPARIN MARKET, BY PACKAGING
18.1 OVERVIEW
18.2 GLASS
18.3 PLASTIC
19 EUROPE HEPARIN MARKET, BY END USER
19.1 OVERVIEW
19.2 HOSPITALS
19.3 CLINICS
19.4 HOMECARE
19.5 AMBULATORY SURGICAL CENTERS
19.6 OTHERS
20 EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 HOSPITAL PHARMACY
20.3 RETAIL PHARMACY & DRUG STORE
20.4 ONLINE
20.5 OTHERS
21 HEPARIN MARKET, BY GEOGRAPHY
21.1 EUROPE
21.1.1 GERMANY
21.1.2 U.K.
21.1.3 FRANCE
21.1.4 SPAIN
21.1.5 ITALY
21.1.6 RUSSIA
21.1.7 SWITZERLAND
21.1.8 NETHERLANDS
21.1.9 TURKEY
21.1.10 BELGIUM
21.1.11 REST OF EUROPE
22 EUROPE HEPARIN MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: EUROPE
23 COMPANY PROFILES
23.1 SANOFI
23.1.1 COMPANY SNAPSHOT
23.1.2 REVENUE ANALYSIS
23.1.3 GEOGRAPHIC PRESENCE
23.1.4 PRODUCT PORTFOLIO
23.1.5 RECENT DEVELOPMENT
23.2 PFIZER INC.
23.2.1 COMPANY SNAPSHOT
23.2.2 REVENUE ANALYSIS
23.2.3 GEOGRAPHICAL PRESENCE
23.2.4 PRODUCT PORTFOLIO
23.2.5 RECENT DEVELOPMENT
23.3 FRESENIUS KABI AG
23.3.1 COMPANY SNAPSHOT
23.3.2 REVENUE ANALYSIS
23.3.3 GEOGRAPHICAL PRESENCE
23.3.4 PRODUCT PORTFOLIO
23.3.5 RECENT DEVELOPMENTS
23.4 F. HOFFMANN-LA ROCHE LTD
23.4.1 COMPANY SNAPSHOT
23.4.2 REVENUE ANALYSIS
23.4.3 GEOGRAPHICAL PRESENCE
23.4.4 PRODUCT PORTFOLIO
23.4.5 RECENT DEVELOPMENTS
23.5 MYLAN N.V.
23.5.1 COMPANY SNAPSHOT
23.5.2 REVENUE ANALYSIS
23.5.3 GEOGRAPHIC PRESENCE
23.5.4 PRODUCT PORTFOLIO
23.5.5 RECENT DEVELOPMENT
23.6 ASPEN HOLDINGS
23.6.1 COMPANY SNAPSHOT
23.6.2 REVENUE ANALYSIS
23.6.3 GEOGRAPHICAL PRESENCE
23.6.4 PRODUCT PORTFOLIO
23.6.5 RECENT DEVELOPMENTS
23.7 CHANGZHAOU QIANHONG BIO-PHARMA CO., LTD.
23.7.1 COMPANY SNAPSHOT
23.7.2 PRODUCT PORTFOLIO
23.7.3 RECENT DEVELOPMENT
23.8 EISAI CO., LTD.
23.8.1 COMPANY SNAPSHOT
23.8.2 REVENUE ANALYSIS
23.8.3 GEOGRAPHICAL PRESENCE
23.8.4 PRODUCT PORTFOLIO
23.8.5 RECENT DEVELOPMENT
23.9 HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO. LTD.
23.9.1 COMPANY SNAPSHOT
23.9.2 PRODUCT PORTFOLIO
23.9.3 RECENT DEVELOPMENTS
23.10 HIKMA PHARMACEUTICALS PLC
23.10.1 COMPANY SNAPSHOT
23.10.2 REVENUE ANALYSIS
23.10.3 GEOGRAPHIC PRESENCE
23.10.4 PRODUCT PORTFOLIO
23.10.5 RECENT DEVELOPMENT
23.11 LEO PHARMA A/S
23.11.1 COMPANY SNAPSHOT
23.11.2 REVENUE ANALYSIS
23.11.3 GEOGRAPHICAL PRESENCE
23.11.4 PRODUCT PORTFOLIO
23.11.5 RECENT DEVELOPMENT
23.12 NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.
23.12.1 COMPANY SNAPSHOT
23.12.2 PRODUCT PORTFOLIO
23.12.3 RECENT DEVELOPMENTS
23.13 NOVARTIS AG
23.13.1 COMPANY SNAPSHOT
23.13.2 REVENUE ANALYSIS
23.13.3 GEOGRAPHICAL PRESENCE
23.13.4 PRODUCT PORTFOLIO
23.13.5 RECENT DEVELOPMENTS
23.14 OPOCRIN S.P.A.
23.14.1 COMPANY SNAPSHOT
23.14.2 PRODUCT PORTFOLIO
23.14.3 RECENT DEVELOPMENT
23.15 SARIA SE & CO. KG
23.15.1 COMPANY SNAPSHOT
23.15.2 PRODUCT PORTFOLIO
23.15.3 RECENT DEVELOPMENT
23.16 SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., LTD.
23.16.1 COMPANY SNAPSHOT
23.16.2 REVENUE ANALYSIS
23.16.3 GEOGRAPHICAL PRESENCE
23.16.4 PRODUCT PORTFOLIO
23.16.5 RECENT DEVELOPMENT
23.17 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
23.17.1 COMPANY SNAPSHOT
23.17.2 PRODUCT PORTFOLIO
23.17.3 RECENT DEVELOPMENT
23.18 SHENZHEN TECHDOW PHARMACEUTICAL CO., LTD
23.18.1 COMPANY SNAPSHOT
23.18.2 GEOGRAPHICAL PRESENCE
23.18.3 PRODUCT PORTFOLIO
23.18.4 RECENT DEVELOPMENTS
23.19 TEVA PHARMACEUTICAL INDUSTRIES LTD
23.19.1 COMPANY SNAPSHOT
23.19.2 REVENUE ANALYSIS
23.19.3 GEOGRAPHICAL PRESENCE
23.19.4 PRODUCT PORTFOLIO
23.19.5 RECENT DEVELOPMENT
23.20 YINO PHARMA LIMITED
23.20.1 COMPANY SNAPSHOT
23.20.2 PRODUCT PORTFOLIO
23.20.3 RECENT DEVELOPMENTS
24 QUESTIONNAIRE
25 CONCLUSION
26 RELATED REPORTS